Shareholders Equity: The sum of preferred and common equity items.
Viking Therapeutics, Inc. (VKTX) had Shareholders Equity of $880.28M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-109.96M |
|
-- |
|
-- |
|
$150.92M |
|
$-150.92M |
|
$40.96M |
|
$-109.96M |
|
$-110.08M |
|
$-109.96M |
|
$-109.96M |
|
$-109.96M |
|
$-110.08M |
|
$-150.92M |
|
$-167.75M |
|
109.04M |
|
109.04M |
|
$-1.01 |
|
$-1.01 |
|
| Balance Sheet Financials | |
$907.22M |
|
-- |
|
$1.10M |
|
$908.32M |
|
$27.41M |
|
-- |
|
$0.63M |
|
$28.04M |
|
$880.28M |
|
$880.28M |
|
|
Shareholders Equity |
$880.28M |
111.57M |
|
| Cash Flow Statement Financials | |
$-87.79M |
|
$-553.37M |
|
$612.46M |
|
$55.52M |
|
$26.68M |
|
$-28.84M |
|
$29.71M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
33.09 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-87.79M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-12.49% |
|
-12.49% |
|
-12.11% |
|
-12.49% |
|
$7.89 |
|
$-0.81 |
|
$-0.81 |
|